AI Trends

a16z Invests Further in Boltz’s $110M Series A

a16z:NewsUpdated Nov 19 00:10

AI summary

Boltz has completed a $110M Series A, with a16z announcing an increased investment in the molecular design AI company. Boltz provides model services through usage-based molecular tokens, while Boltz Lab and the Boltz API also support calls by agents such as Claude Code and Codex. Since the release of BoltzMol-1 and BoltzProt-1, its customers’ weekly molecular token consumption has grown approximately 50-fold over the past four months.

Why read this

AI score 60

The article traces model usage and pharmaceutical company deployments to show how a usage-based molecular design platform is entering drug discovery workflows.

Topics

Tags

Body

The drug discovery process is famously expensive, risky, and long. Much has been written about AI’s potential to disrupt it. Billions of dollars have been raised to advance proprietary pipelines of AI-designed programs. Frontier labs are focused on this fight.

All with good reason. The size of the prize can be massive. For decades the arduous path to a drug often began with a needle-in-a-haystack search through millions of compounds, followed by lengthy experimental campaigns to optimize molecules. AI is enabling a fundamentally different approach to drug discovery through molecular design. Building on breakthroughs such as AlphaFold, a new generation of AI models is expanding what scientists can predict and design computationally.

Boltz is helping lead that shift with the world’s most widely adopted molecular models, putting frontier molecular intelligence in the hands of all scientists. Scientists can now start with the properties a medicine needs and use these models to predict molecular interactions, generate molecules against specified criteria, and refine their designs across multiple objectives before committing to synthesis and testing. The promise is a faster path to better development candidates, with fewer unproductive experiments along the way and, ultimately, a better probability of success in human trials.

We saw the demand for these capabilities while Boltz was still a research project at MIT. We knew something special was happening when our pharma partners and therapeutics portfolio founders kept telling us they were all using the same open-source AI models out of MIT. Boltz’s model launches drew standing-room-only crowds in the largest auditoriums across cities around the world. By the time we co-led Boltz’s seed round last year, its open-source models had reached every top 20 pharmaceutical company.

Behind that adoption were Gabriele Corso, Jeremy Wohlwend, and Saro Passaro, in whom we saw an unusual combination of frontier AI research ability, deep understanding of molecular science, and the determination to put their work into scientists’ hands. Since then, the founders have attracted an unrivaled concentration of research and engineering talent, building a team capable of advancing the underlying science while turning those advances into products that scientists can use every day.

Molecular tokens: intelligence, by the dose

AI is becoming a new kind of scientific reagent: intelligence scientists can buy and consume by the experiment. Boltz measures that activity in molecular tokens, the units of molecular information processed by its models. Molecular tokens offer a way to put frontier biomolecular models into the hands of any scientist, with consumption scaling to the work being asked of them. A quick prediction might require relatively little; a campaign to discover and refine a molecule against an increasingly demanding set of requirements could consume far more. Scientists could budget for computational exploration much as they already budget for sequencing reads or assay reagents.

Boltz believes this technology is too powerful to be held captive by a single company’s proprietary pipeline. Or to be limited to a few targets, and the associated complexities and frictions, that come from traditional pharma partnerships. Boltz is breaking that mold by pioneering a usage-based business model designed to put powerful molecular design capabilities into the hands of as many scientists as possible. By making its models readily accessible and charging for model usage, Boltz can grow alongside their use across the industry, while scientists retain ownership of what they create.

That breadth matters because the opportunity extends well beyond the hardest targets that typically motivate bespoke partnerships. Boltz wants scientists to use its models from the beginning of a discovery campaign, making molecular prediction and design a routine part of how they explore ideas and choose what to pursue. The ambition is for scientists to reach for these capabilities as naturally as they reach for other reagents.

Boltz has also built the slick interfaces that make these capabilities accessible to a broader scientific audience. Boltz Lab allows biologists and chemists to work directly with the models via a user-friendly interface, while the Boltz API makes those same capabilities available within existing computational workflows and through agentic harnesses such as Claude Code and Codex. These agents can set up jobs, call models, retrieve results, and help scientists iterate, reducing the expertise and effort required to turn a scientific hypothesis into a computational experiment.

Some of the most impressive recent demonstrations of AI—including tackling longstanding mathematical problems—have involved agents working for hours or days, with the time and compute to explore, test, and refine their ideas. Boltz is observing a similar pattern in molecular design. Additional compute for virtual screens and design campaigns can improve the quality of the candidates its models prioritize, giving scientists a reason to invest in deeper computational exploration before moving into the lab.

Following the launch of BoltzMol-1 and BoltzProt-1, weekly molecular token consumption by Boltz customers has risen exponentially, roughly 50-fold in just the last 4 months!

This growth suggests a growing appetite for molecular compute, and offers early validation of Boltz’s usage-based business model, as pharma and biotech companies incorporate molecular intelligence into their discovery workflows. Boltz can train exclusive versions of its models on a partner’s proprietary data, giving pharma companies specialized molecular intelligence shaped by their own accumulated research.

Boltz’s commercial models are already deployed at Pfizer, GSK, Takeda, BMS, and other leading pharmaceutical and multinational companies. More will certainly follow.

The opportunity now is to invest more deeply in research, compute, and data, building even more capable models that improve the molecules scientists can design and expand the problems they can pursue.

Congratulations to Gabriele, Jeremy, Saro, and the entire Boltz team on their $110M Series A. We’re proud to double down on Boltz’s ambition to make frontier biomolecular intelligence as accessible, and as routine to use, as the reagents on a laboratory bench.

And you too can join the adventure: check out Boltz’s open career opportunities!

is a general partner on the Bio + Health team at Andreessen Horowitz, focused on therapeutics, diagnostics, life sciences tools, and software.

X

Linkedin

Operating on DNA is more like surgery than medicine Jorge Conde

is an investing partner on the Bio + Health team, focused on biotechnology companies.

X

Linkedin

Want More a16z Bio + Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future. Learn More

Infra

new Investing in First Person Labs

Joel de la Garza and Martin Casado

Infra

new Investing in General Translation

new Investing in First Person Labs

Joel de la Garza and Martin Casado

Infra

new Investing in General Translation

Investing in Tutor Intelligence

new Investing in First Person Labs

Joel de la Garza and Martin Casado

Infra

new Investing in General Translation

Investing in Tutor Intelligence

Infra

Investing in Preference Model

Jennifer Li

Bio + Health

Investing in General Medicine

Frontier

Investing in Conway, the Creator of Underdog

Infra

Investing in doxxnet

Joel de la Garza and Martin Casado

Growth

Investing in Armadin

David George and Stephenie Zhang

General

Incubating The Horowitz Andreessen Academy

Erik Torenberg

Expert News by a16z

Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.

Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.

There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.

With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.

For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.

Source

a16z:News